Related Experiment Video
Updated: Jun 13, 2025
08:03
Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
Published on: June 6, 2018
14.2K
Anti-hypertensive medications and erectile dysfunction: focus on β-blockers.
G Corona1, W Vena2,3, A Pizzocaro4
1Endocrinology Unit, Maggiore Hospital, Azienda-Usl Bologna, Bologna, Italy.
Endocrine
|September 13, 2024
Summary
Certain blood pressure medications can cause erectile dysfunction (ED), with beta-blockers (BBs) being most frequently associated. Open communication between patients and physicians is key to managing potential sexual side effects.
Area of Science:
- Pharmacology and Urology
- Cardiovascular Medicine
Background:
- Hypertension management often involves medications with potential side effects.
- Erectile dysfunction (ED) is a concern, and its link to antihypertensive drugs is debated.
- Specific drug classes, including thiazides and beta-blockers (BBs), have been implicated.
Purpose of the Study:
- To critically analyze the available evidence on antihypertensive medications and their association with ED.
- To provide an evidence-based summary of the real contribution of these drugs to erectile dysfunction.
Main Methods:
- Comprehensive narrative review of Medline, Embase, and Cochrane databases.
- Specific systematic review focused on the impact of beta-blockers (BBs) on erectile dysfunction.
Main Results:
- Centrally acting drugs (clonidine, α-methyldopa) have documented negative effects on erectile function.
- ACE inhibitors (ACEis), ARBs, and CCBs show neutral to positive effects on erectile function.
- Thiazides do not appear to negatively impact erectile function based on recent evidence; BBs remain most associated with ED, though nebivolol may offer better outcomes.
Conclusions:
- Sexual function should be routinely assessed in hypertensive patients.
- Open patient-physician dialogue is crucial for managing potential medication side effects.
- Effective management strategies can overcome negative sexual outcomes associated with antihypertensive therapy.
Related Concept Videos
01:28Antihypertensive Drugs: Types of β-Blockers
603
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
603
01:17Antihypertensive Drugs: Action of β1 Blockers
320
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
320
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
543
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
543
01:22Heart Failure Drugs: β-Blockers
321
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
321
01:16Antianginal Drugs: Nitrates and β-Blockers
543
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
543
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
559
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
559